Lantern Pharma Launches withZeta.ai, World's First Multi-Agentic AI Co-Scientist for Rare Cancer Drug Discovery
The first multi-agentic AI platform designed specifically for discovering treatments for rare cancers is now available.
Lantern Pharma has officially launched withZeta.ai, a groundbreaking platform it calls the world's first multi-agentic AI co-scientist dedicated to discovering and developing drugs for rare cancers. The system, now available via subscription, is powered by a proprietary oncology ontology and knowledge base, allowing it to perform complex tasks like characterizing rare cancer types, identifying potential drug candidates, and designing optimized combination therapies. The launch is being highlighted with a public demonstration at the prestigious American Association for Cancer Research (AACR) Annual Meeting from April 17-22, 2026.
The 'multi-agentic' architecture means withZeta.ai uses multiple specialized AI agents (software programs that can take actions) that work together, simulating a collaborative team of scientists. This approach allows the platform to tackle the multifaceted challenge of drug discovery, from initial target identification to therapy optimization, in an integrated workflow. By focusing specifically on rare cancers—an area often underserved due to high costs and small patient populations—Lantern Pharma aims to use AI to dramatically accelerate and de-risk the development pipeline, potentially bringing new treatments to patients faster.
- Lantern Pharma launched withZeta.ai, the first multi-agentic AI co-scientist for rare cancer drug discovery.
- The platform is powered by a proprietary oncology ontology and knowledge base for characterizing cancers and finding drugs.
- It is being demonstrated at the AACR Annual Meeting (April 17-22, 2026) and subscriptions are now available.
Why It Matters
It could drastically accelerate and reduce the cost of developing life-saving treatments for underserved rare cancer patients.